Plant Based Therapeutics on T-Cell Prolymphocytic Leukemia

Selvakumar Sivagnanam*
Department of Industrial Bio-Technology, Bharath University, India

*Corresponding author: Selvakumar Sivagnanam, Department of Industrial Bio-Technology, Bharath University, India

Published: 01 Aug, 2017
Cite this article as: Sivagnanam S. Plant Based Therapeutics on T-Cell Prolymphocytic Leukemia. Clin Oncol. 2017; 2: 1321.


T-cell prolymphocytic Leukemia is a mature T-cell leukemia with aggressive behavior and predilection for blood, bone marrow, lymph nodes, liver, spleen and skin involvement. T-Cell Prolymphocytic Leukemia is most common type of mature T-cell leukemia, primarily affecting adult over the age of thirty. It represents two percentage of all lymphocytic leukemia in adults and found to be a difficult to cure form of human-T-Cell Prolymphocytic Leukemia. Natural plant derived Components that inhibit tumour initiation are traditionally termed blocking agents. They may act by preventing the interaction between chemical carcinogens or endogenous free radicals and nucleic acids, thereby reducing the levels of damage and resulting mutations which contribute not only to tumour initiation but also progressive instability of genome and over all tumorous transformation. Protection may be achieved as a consequence of decreased cellular uptake and metabolic activation of pro carcinogens and or increased detoxification of reactive electrophones and free radical scavenging, as well as induction of repair pathways. Therefore, identification, characterization and development of a novel chemotherapeutic agent which is affordable, easily available and with no side effects or less side effects for this disease is of paramount importance. The T-Cell Prolymphocytic Leukemia is very difficult to treat and diagnose and it does not respond to most available modern chemotherapeutic drugs. The present abstract aims at possible successful treatment of T-Cell Prolymphocytic Leukemia on selected Indian traditional medicinal plants. This strategy, if proved relevant, may cure the disease, may reduce the cancer burden to the patient and may even increase the median life span with no or less side effects. Therefore, we envisage extending the study of the chemotherapeutic efficacy of the isolated, charecterised and desired plant metabolites against T-Cell Prolymphocytic Leukemia. If this study proves to be fruitful, it can open up a new and successful strategy in the treatment of T-Cell Prolymphocytic Leukemia patients worldwide.